tried MASH for 15 weeks. here is what happened.
Long-ish post, sorry. tl;dr at the bottom. I have been tracking survodutide against ApoB for 31 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here. Caveats up front: one person, one lab, one…
the MASH indication changes the risk calculus
rodent dual agonist is investigation only
the safety profile is not just tirzepatide amplified
Came off after 5 weeks for financial reasons. Regained about a third over the following year. Back on now at a much lower dose.